Entity

Time filter

Source Type


Degirmenci M.,Izmir Tepecik Training and Research Hospital | Varol U.,Izmir Katip Celebi University | Ozguzer A.,Izmir Tepecik Tepecik Training and Research Hospital | Bozkurt M.,Izmir Tepecik Training and Research | Sezgin C.,Ege University
Turk Onkoloji Dergisi | Year: 2014

Despite recent advances in therapeutics, the prognosis of patients with advanced pancreatic cancer has remained poor. Median survival of patient is 3-6 months and five year survival rate is less than 5%. We report a case of fifty-five-yearold male with complaints of abdominal pain and weight loss. Patient was diagnosed as pancreas adenocarcinoma with multiple hepatic metastases. Then, the patient received gemcitabine 1250 mg/m2 at day 1 and 8; cisplatin 80 mg/m2 at day 1 and a cycle of therapy was defined as 21 days. After six cycles, partial response was achieved, but associated with grade 3 neutropenia. So, cisplatin was stopped and patient was treated with gemcitabine monotherapy. After 18 cycles, complete response in hepatic metastases was observed with magnetic resonance imaging. Due to hematologic and renal toxicity, only gemcitabine monotherapy was continued in our patient, but still indicating complete remission in his fifth year. © 2014 Association of Oncology. Source

Discover hidden collaborations